Pricing Log in Create free account
Friday 6 November 2026 Export CLPT’s income statement to Excel — free account

ClearPoint Neuro, Inc.

CLPT Healthcare Medical Devices

ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024.

Revenue
+36.3%
EPS
−14.7%
Free cash flow
−58.1%
Total debt
+74.1%

Quarter to September 2026, against a year earlier

8.43 0.26 −2.99%
Market cap
$278.6M
P/E
0.0×
Fwd P/E
−9.1×
Dividend yield
—
F-score
4/9
Altman Z
0.44
Beneish M
−1.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.47
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 2 1 — — 2 3 — — — — —
Insider Ownership 8.21%

Capital & Financial Ratios $m

Size
Market Cap 278.55
Revenue ttm 45.49
Net income ttm (36.13)
Free cash flow ttm (33.22)
Net debt Q 4.66
Valuation
P/E 0.00
Forward P/E (9.12) (negative: loss-making)
Price / sales 5.92
Forward P/S Powerpack
Price / FCF 0.00
Price / book 9.87 (above 6: high)
Financial health
Current ratio Q 6.76 (at or above 1.5: strong)
Debt / equity Q 1.86
Interest coverage Q (4.38)
Growth
Revenue growth Q +36.27% (above 0%: growing)
Operating income growth Q −20.02% (below 0%: shrinking)
EPS, this year −29.44% (below 0%: weak)
EPS, next year A +21.03% (at or above 15%: strong)
Revenue, next year A +31.18% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +1.50%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.0×, against a ten-year median of 6.9×; over the ten years it ranged from 1.1× in 2017 to 29.6× in 2021.
P/S against its own 10 years 42.28%
10-year low 10-year high
P/B against its own 10 years 56.36%
10-year low 10-year high
EV/Sales against its own 10 years 44.88%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 23 20 46 46
Receivables 3 5 7 8
Inventory 8 7 8 10
Other — — — —
36 33 64 67
2023 2024 2025 Q'26
Payables 0 1 1 1
ST’ Debt — — — —
Other — — — 2
7 10 11 10

Compound Annual Growth %

10y 5y 3y
Sales 23.19% 23.58% 21.62%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 63.79% (8.76%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.32 Actual −0.24

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.22 −0.27 Miss by 0.05
Q1 FY26 −0.28 −0.32 Miss by 0.04
Q2 FY26 −0.29 −0.38 Miss by 0.09
Q3 FY26 −0.32 −0.24 Beat by 0.08
Q4 FY26 −0.23 — Reports 16 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.32) (0.38) (0.24) — —
’25 (0.22) (0.21) (0.21) (0.27) (0.90)
’24 (0.16) (0.16) (0.18) (0.20) (0.70)
’23 (0.23) (0.29) (0.20) (0.19) (0.90)
’22 (0.17) (0.18) (0.15) (0.18) (0.68)
’21 (0.13) (0.17) (0.18) (0.19) (0.69)
’20 (0.13) (0.11) (0.09) (0.09) (0.43)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 12 11 12 — —
’25 8 9 9 10 37
’24 8 8 8 8 31
’23 5 6 6 7 24
’22 5 5 5 5 21
’21 4 3 5 4 16
’20 3 2 4 4 13
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (7) (5) — —
’25 (6) (3) (3) (12) (24)
’24 (4) (3) (1) (1) (9)
’23 (6) (5) (2) (1) (14)
’22 (4) (5) (4) (3) (16)
’21 (2) (4) (3) (4) (13)
’20 (2) (2) (1) (2) (8)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (7) (5) — —
’25 (6) (3) (3) (12) (24)
’24 (4) (3) (1) (2) (9)
’23 (6) (6) (2) (1) (15)
’22 (4) (5) (4) (3) (17)
’21 (2) (4) (3) (4) (13)
’20 (3) (2) (1) (2) (8)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 7 7 11 13 16 21 24 31 37 45 +23.0% 49 56 64 +20.3%
Gross margin, % 54.03 60.72 66.91 64.86 71.09 68.24 65.84 56.83 60.92 61.38 61.39 +7.4 pt
EBT (8) (7) (6) (6) (7) (14) (16) (22) (19) (25) (36) +13.6%
EBT margin, % (140.36) (97.13) (83.82) (49.39) (52.86) (88.41) (79.97) (92.21) (60.22) (68.93) (79.50) +71.4 pt
Net income (8) (7) (6) (6) (7) (14) (16) (22) (19) (26) (36) +13.7%
Per share, $
Per share, $ Revenue 2.09 0.95 0.67 0.85 0.81 0.79 0.85 0.97 1.16 1.31 1.47 (5.1%)
Earnings (2.93) (0.93) (0.56) (0.42) (0.43) (0.69) (0.68) (0.90) (0.70) (0.90) (1.21) (12.3%)
Cash flow (2.11) (0.77) (0.42) (0.22) (0.49) (0.61) (0.67) (0.56) (0.33) (0.84) (1.04) (9.7%)
Capex (0.04) 0.00 (0.01) (0.01) (0.03) (0.01) (0.05) (0.04) (0.01) (0.02) (0.03) (7.4%)
Free cash flow (2.15) (0.78) (0.43) (0.23) (0.52) (0.62) (0.72) (0.60) (0.34) (0.86) (1.07) (9.6%)
Book value (0.27) 0.75 0.14 0.35 0.15 2.35 1.53 0.86 0.94 0.99 0.88 n/m
Shares, m 3 8 11 13 16 21 24 25 27 28 30 +29.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 1.63 2.77 2.33 5.63 19.63 14.27 9.79 6.94 13.24 10.48 5.92 8.7
P/B 0.00 3.50 11.35 13.77 105.96 4.77 5.45 7.86 16.37 13.82 9.87 18.3
EV/Sales 2.57 2.18 2.66 5.32 19.73 11.56 8.45 6.40 12.92 10.56 6.02 8.2
EV/FCF (2.49) (2.67) (4.16) (19.73) (30.50) (14.16) (10.03) (10.22) (40.44) (15.63) (8.11) (15.0)
Cash, $m
Cash, $m Operating cash flow (6) (6) (5) (3) (8) (13) (16) (14) (9) (24) (32) +17.0%
Capex 0 0 0 0 0 0 (1) (1) 0 (1) (1) +20.0%
Free cash flow (6) (6) (5) (3) (8) (13) (17) (15) (9) (24) (33) +17.1%
Balance, $m
Balance, $m Working capital 3 8 5 7 22 57 44 29 23 53 57 +37.2%
Net debt 1 (4) 0 (4) 1 (44) (28) (13) (20) 3 5 +11.6%
Shareholders’ equity (1) 6 2 5 2 49 37 21 25 28 27 n/m
Returns, %
Returns, % ROA (93.09) (67.30) (56.66) (56.01) (32.73) (30.31) (27.15) (45.01) (46.22) (37.30) (41.75) +55.8 pt
ROIC (1,114.66) (271.78) (173.49) (298.16) (109.26) (185.09) (109.86) (175.75) (233.37) (48.45) (62.84) +1,066.2 pt
ROE 589.65 (282.59) (167.95) (181.73) (194.80) (56.33) (38.37) (76.09) (81.24) (95.64) (167.52) (685.3) pt
People
People Employees 33 34 38 49 67 80 108 107 115 172 — +20.1%
Revenue/emp, $m 0.17 0.22 0.19 0.23 0.19 0.20 0.19 0.22 0.27 0.21 — +2.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

ClearPoint Neuro, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RCEL Avita Medical Inc. $389.5M — (loss-making) — (loss-making) +53.05% (above 0%: growing) n/m +86.66% (above 0%: growing) 84.02% (17.95%) Compare
MOBI Mobia Medical, Inc $375.5M — (loss-making) — (loss-making) +175.85% (above 0%: growing) n/m −18.01% (below 0%: shrinking) 83.25% (118.67%) Compare
OFIX ORTHOFIX MEDICAL INC. $363.3M — (loss-making) — (loss-making) +3.85% (above 0%: growing) n/m −516.58% (below 0%: shrinking) 70.97% (3.86%) Compare
VMD Viemed Healthcare, Inc. $343.2M 22.0× 23.4× +12.18% (above 0%: growing) +33.33% (above 0%: growing) −67.55% (below 0%: shrinking) 57.26% 0.00% Compare
CV CapsoVision, Inc. $329.9M — (loss-making) — (loss-making) +9.89% (above 0%: growing) n/m −84.44% (below 0%: shrinking) 51.36% (208.07%) Compare
CLPT ClearPoint Neuro, Inc. $278.6M — (loss-making) — (loss-making) +36.27% (above 0%: growing) n/m −58.10% (below 0%: shrinking) 58.46% (52.44%)
TMCI Treace Medical Concepts, Inc. $271.9M — (loss-making) — (loss-making) −4.24% (below 0%: shrinking) n/m +11.74% (above 0%: growing) 78.47% (32.96%) Compare
INFU InfuSystems Holdings, Inc. $270.1M 32.0× 33.0× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
QSI Quantum-Si Incorporated $256.1M — (loss-making) — (loss-making) −61.59% (below 0%: shrinking) n/m +37.48% (above 0%: growing) 34.91% (11,215.09%) Compare
Median of peers $336.5M — — +6.87% — −42.27% 64.47% (25.45%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 10 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.81m 2.13m 161.51
2024 2.53m 5.88m 137.08
2023 2.00m 1.46m 42.73

Ownership

Directors and executive officers, together 6.94%
Bigger Capital Fund, LP 7.39%
MAK Capital One L.L.C. 5.77%
Blackrock, Inc. 5.28%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

ClearPoint Neuro, Inc. (CLPT) Latest News

29 Oct

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby

28 Oct

Impact 4 · · MarketBeat
Impact 4 · · ACCESS Newswire
Impact 3 · · Zacks

29 Sep

Impact 4 · · InvestorsHub

4 Sep

Impact 3 ·

10 Aug

Impact 4 · · The Motley Fool transcript

4 Aug

Impact 3 · · Moby transcript

3 Aug

Impact 3 ·
Impact 3 · · MarketBeat transcript
Impact 3 ·

31 Jul

Impact 3 ·

17 Jun

Impact 4 · · InvestorsHub

27 May

Impact 4 · · ACCESS Newswire

26 May

Impact 3 · · Simply Wall St.

18 May

Impact 4 · · GuruFocus.com

14 May

Impact 3 · · Moby transcript

13 May

Impact 4 · · MarketBeat
Impact 4 · · Benzinga transcript
Impact 4 · · ACCESS Newswire
Impact 4 ·
Impact 3 · · Zacks
Impact 3 · · Zacks

22 Apr

Impact 4 · · ACCESS Newswire

20 Apr

Impact 4 ·

6 Apr

Impact 4 · · Simply Wall St.

23 Mar

Impact 4 · · Simply Wall St.

18 Mar

Impact 4 · · MarketBeat

17 Mar

Impact 4 · · Moby
stockrow.com/CLPT · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com